Ask AI
Back Back
Genetics in pediatric SNHL 3

CE / CME

Integrating Genetics Into Pediatric SNHL Care Planning: The Role of Audiology

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Physicians: maximum of 0.50 AMA PRA Category 1 Credit™

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: July 30, 2026

Expiration: July 29, 2027

Jennifer L. Butler
Jennifer L. Butler, AuD, CCC-A, CH-AP
CME/CE Information

Activity

Progress
1 2 3
Course Completed
Continue to Post-test

References

  1. Joint Committee on Infant Hearing. Year 2019 position statement: Principles and guidelines for early hearing detection and intervention programs. J Early Hear Detect Interv. 2019;4:1-44.
  2. Li MM, Tayoun AA, DiStefano M, et al; ACMG Professional Practice and Guidelines Committee. Clinical evaluation and etiologic diagnosis of hearing loss: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022;24:1392-1406.
  3. Shearer AE, Hildebrand MS, Odell AM, et al. Genetic hearing loss overview. In: Adam MP, Bick S, Mirzaa GM, et al, editors. GeneReviews [internet]. University of Washington, Seattle; 1993-2026.
  4. American Speech-Language-Hearing Association. Language and communication of deaf and hard of hearing children. asha.org/practice-portal/professional-issues/language-communication-deaf-hard-of-hearing-children. Accessed July 2, 2026.
  5. Carlson RJ, Walsh T, Mandell JB, et al. Association of Genetic Diagnoses for Childhood-onset hearing loss with cochlear implant outcomes. JAMA Otolaryngol Head Neck Surg. 2023;149:212-222.
  6. Shearer AE, Hildebrand MS, Odell AM, et al. Genetic hearing loss overview. In: Adam MP, Bick S, Mirzaa GM, et al, editors. GeneReviews [internet]. University of Washington, Seattle; 1993-2026.
  7. Smith RJH, Azaiez H, Booth K. GJB2-related autosomal recessive nonsyndromic hearing loss. In: Adam MP, Bick S, Mirzaa GM, et al, editors. GeneReviews [internet]. University of Washington, Seattle; 1993-2026.
  8. Watanabe K, Nishio SY, Usami SI; Deafness Gene Study Consortium. The prevalence and clinical features of MYO7A-related hearing loss including DFNA11, DFNB2 and USH1B. Sci Rep. 2024;14:8326.
  9. Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-424.
  10. Hoskinson DC, Dubuc AM, Mason-Suares H. The current state of clinical interpretation of sequence variants. Curr Opin Genet Dev. 2017;42:33-39.
  11. Martschenko DO, Smith M. Genes do not operate in a vacuum, and neither should our research. Nat Genet. 2021;53:255-256.
  12. Kochhar A, Hildebrand MS, Smith RJ. Clinical aspects of hereditary hearing loss. Genet Med. 2007;9:393-408.
  13. Manrique M, Ramos Á, de Paula Vernetta C, et al. Guideline on cochlear implants. Acta Otorrinolaringol Esp (Engl Ed). 2019;70:47-54.
  14. American Academy of Audiology. Clinical practice guideline: cochlear implants. audiology.org/practice-guideline/clinical-practice-guideline-cochlear-implants/. Accessed July 2, 2026.
  15. Koenekoop RK, Arriaga MA, Trzupek KM, et al. Usher syndrome type I. In: Adam MP, Bick S, Mirzaa GM, et al, editors. GeneReviews [internet]. University of Washington, Seattle; 1993-2026.
  16. FDA. FDA approved first-ever gene therapy for treatment of genetic hearing loss under national priority voucher program. fda.gov/news-events/press-announcements/fda-approves-first-ever-gene-therapy-treatment-genetic-hearing-loss-under-national-priority-voucher.
  17. Lunsotogene parvec-cwha [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2026.

BACK | NEXT
Continue to Post-test